Quince’s steroid therapy for rare disease fails, shares tanknews2026-01-30T16:17:55+00:00January 30th, 2026|Endpoints News|
Sanofi vows to stay committed to vaccines as portfolio takes a hitnews2026-01-29T16:18:36+00:00January 29th, 2026|Endpoints News|
Updated: Roche predicts its breast cancer pill could become its biggest-selling drugnews2026-01-29T12:11:54+00:00January 29th, 2026|Endpoints News|
FDA asks court to pause Louisiana’s abortion pill fightnews2026-01-28T19:18:46+00:00January 28th, 2026|Endpoints News|
Hengrui blazes trail as Chinese drugmakers aspire to go multinationalnews2026-01-28T15:00:06+00:00January 28th, 2026|Endpoints News|
Lilly partners with recombinase-based gene editing startup Seamless Therapeuticsnews2026-01-28T12:00:19+00:00January 28th, 2026|Endpoints News|
Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage datanews2026-01-28T11:59:20+00:00January 28th, 2026|Endpoints News|
Cardiff execs depart as company drops mixed Phase 2 datanews2026-01-27T18:22:21+00:00January 27th, 2026|Endpoints News|
FDA greenlights Life Biosciences’ gene therapy study to rewind the age of cellsnews2026-01-27T13:00:47+00:00January 27th, 2026|Endpoints News|
Updated: Roche’s obesity shot posts decent weight loss in mid-stage test, heads to Phase 3news2026-01-27T12:09:37+00:00January 27th, 2026|Endpoints News|
